References
- De Vita VJ Jr HS, SA R. Cancer: Principles and practice of oncology. 6th ed. Philadelphia, P.A: Lippincott-Raven; 2001
- Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242–53
- Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102: V215–V224
- Cool RM, Herrington JD, Wong L. Recurrent peripheral arterial thrombosis induced by cisplatin and etoposide. Pharmacotherapy 2002; 22: 1200–4
- Hennessy B, O'Connor M, Carney DN. Acute vascular events associated with cisplatin therapy in malignant disease. Ir Med J 2002;95:145–6, 148.
- Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 1998; 160: 2021–4
- Longo F, Mansueto G, Poggi A, Pellegrini P, Falzetta A, Rozzi A, et al. Acute arterial thrombosis in a patient with small cell lung cancer after a cycle of chemotherapy with cisplatin and etoposide. Tumori 1999; 85: 214–5
- Apiyasawat S, Wongpraparut N, Jacobson L, Berkowitz H, Jacobs LE, Kotler MN, et al. Cisplatin induced localized aortic thrombus. Echocardiography 2003; 20: 199–200
- Bayne MC. Chemotherapy associated arterial thrombosis. Clin Oncol (R Coll Radiol) 2002; 14: 261–2
- Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: A cohort study and review of the literature. J Clin Oncol 2000; 18: 2169–78
- Cantwell BM, Mannix KA, Roberts JT, Ghani SE, Harris AL, et al. Thromboembolic events during combination chemotherapy for germ cell-malignancy. Lancet 1988; 2: 1086–7
- Piketty AC, Flechon A, Laplanche A, Nouyrigat E, Droz JP, Théodore C, et al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 2005; 93: 909–14
- Illarramendi JJ, Gallego J. Cisplatin-based chemotherapy and acute cerebrovascular events. Lancet 1991; 338: 705
- Boyer M, Raghavan D, Harris PJ, Lietch J, Bleasel A, Walsh JC, et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990; 8: 21–6
- Nichols CR, Roth BJ, Williams SD, Gill I, Muggia FM, Stablein DM, et al. No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the Testicular Cancer Intergroup Study. J Clin Oncol 1992; 10: 760–5
- Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490–505